CETN4P: A Potential Drug Target Or Biomarker (G729338)

Target Name: CETN4P

NCBI ID: G729338

CETN4P

Other Name(s): centrin 4, pseudogene | Centrin 4, pseudogene

CETN4P: A Potential Drug Target Or Biomarker

Centrin 4 (CETN4P) is a protein that is expressed in most tissues of the human body. It is a member of the centrin family, which is a group of proteins that are involved in the organization of microtubules in cells. The discovery of CETN4P as a potential drug target or biomarker has significant implications for the development of new treatments for various diseases.

CETN4P is a 21-kDa protein that is expressed in most tissues of the human body. It is characterized by a unique N-terminus that consists of a 24 amino acid residue and a 5'-end that is rich in basic amino acids. The CETN4P protein is expressed in a variety of tissues, including muscle, pancreas, and brain, and is involved in the regulation of microtubule dynamics.

One of the unique features of CETN4P is its ability to interact with microtubules. It has been shown to form a complex with the protein tyrosine kinase (TKP) that is involved in the regulation of microtubule dynamics. This interaction between CETN4P and TKP suggests that CETN4P may be a useful drug target or biomarker for the treatment of microtubule-related diseases.

In addition to its role in microtubule dynamics, CETN4P has also been shown to be involved in the regulation of actinin cytoskeleton. It has been shown to interact with the protein F-actinin, which is involved in the regulation of actinin cytoskeleton integrity. This interaction between CETN4P and F-actinin suggests that CETN4P may be a useful drug target or biomarker for the treatment of diseases that are characterized by actinin cytoskeleton dysfunction.

CETN4P has also been shown to be involved in the regulation of the actinin-associated protein (AAP) complex. The AAP complex is a protein that is involved in the regulation of actinin cytoskeleton organization and dynamics. CETN4P has been shown to interact with the protein N-cadherin, which is a member of the AAP complex. This interaction between CETN4P and N-cadherin suggests that CETN4P may be a useful drug target or biomarker for the treatment of diseases that are characterized by actinin cytoskeleton dysfunction.

In conclusion, the discovery of CETN4P as a potential drug target or biomarker has significant implications for the development of new treatments for various diseases. Further research is needed to fully understand the role of CETN4P in the regulation of microtubule dynamics and cytoskeleton organization, and to determine the efficacy of CETN4P as a drug or biomarker.

Protein Name: Centrin 4, Pseudogene

The "CETN4P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CETN4P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets